Electroporation-enhanced transdermal diclofenac sodium delivery into the knee joint in a rat model of acute arthritis

Purpose: Since electroporation (EP) can increase the permeability of biological membranes, we hypothesized that it offers an opportunity to enhance the transdermal delivery of drugs for intra-articular indications. Our aim was to compare the anti-inflammatory and analgesic efficacy of EP-combined to...

Teljes leírás

Elmentve itt :
Bibliográfiai részletek
Szerzők: Hartmann Petra
Butt Edina
Fehér Ágnes
Szilágyi Ágnes
Jász Kurszán Dávid
Balázs Boglárka
Bakonyi Mónika
Berkó Szilvia
Erős Gábor
Boros Mihály
Horváth Gyöngyi
Varga Endre
Csányi Erzsébet
Dokumentumtípus: Cikk
Megjelent: 2018
Sorozat:DRUG DESIGN DEVELOPMENT AND THERAPY 12
doi:10.2147/DDDT.S161703

mtmt:3394721
Online Access:http://publicatio.bibl.u-szeged.hu/13810
LEADER 03462nab a2200349 i 4500
001 publ13810
005 20180908145514.0
008 180908s2018 hu o 0|| zxx d
022 |a 1177-8881 
024 7 |a 10.2147/DDDT.S161703  |2 doi 
024 7 |a 3394721  |2 mtmt 
040 |a SZTE Publicatio Repozitórium  |b hun 
041 |a zxx 
100 1 |a Hartmann Petra 
245 1 0 |a Electroporation-enhanced transdermal diclofenac sodium delivery into the knee joint in a rat model of acute arthritis  |h [elektronikus dokumentum] /  |c  Hartmann Petra 
260 |c 2018 
300 |a 1917-1930 
490 0 |a DRUG DESIGN DEVELOPMENT AND THERAPY  |v 12 
520 3 |a Purpose: Since electroporation (EP) can increase the permeability of biological membranes, we hypothesized that it offers an opportunity to enhance the transdermal delivery of drugs for intra-articular indications. Our aim was to compare the anti-inflammatory and analgesic efficacy of EP-combined topical administration of diclofenac sodium hydrogel (50 mg mL(-1) in 230 microL volume) with that of an equivalent dose of oral (75 mg kg(-1)) and simple topical administration. Methods: Arthritis was induced with the injection of 2% lambda-carrageenan and 4% kaolin into the right knee joints of male Sprague Dawley rats. EP was applied for 8 min with 900 V high-voltage pulses for 5 ms followed by a 20 ms break. Drug penetration into the synovial fluid and plasma was detected by high-performance liquid chromatography. Leukocyte-endothelial interactions were visualized by intravital videomicroscopy on the internal surface of the synovium. Inflammation-induced thermal and mechanical hyperalgesia reactions, knee joint edema, and inflammatory enzyme activities were assessed at 24 and 48 h after arthritis induction. Results: EP significantly increased the plasma level of diclofenac as compared with the topical controls 10 min after the 2% lambda-carrageenan and 4% kaolin injection. Increased leukocyte-endothelial interactions were accompanied by joint inflammation, which was significantly reduced by oral and EP diclofenac (by 45% and by 30%, respectively) and only slightly ameliorated by simple topical diclofenac treatment (by 18%). The arthritis-related secondary hyperalgesic reactions were significantly ameliorated by oral and EP-enhanced topical diclofenac treatments. The knee cross-section area (which increased by 35%) was also reduced with both approaches. However, simple topical application did not influence the development of joint edema and secondary hyperalgesia. Conclusion: The study provides evidence for the first time of the potent anti-inflammatory and analgesic effects of EP-enhanced topical diclofenac during arthritis. The therapeutic benefit provided by EP is comparable with that of oral diclofenac; EP is a useful alternative to conventional routes of administration. 
700 0 1 |a Butt Edina  |e aut 
700 0 1 |a Fehér Ágnes  |e aut 
700 0 1 |a Szilágyi Ágnes  |e aut 
700 0 1 |a Jász Kurszán Dávid  |e aut 
700 0 1 |a Balázs Boglárka  |e aut 
700 0 1 |a Bakonyi Mónika  |e aut 
700 0 1 |a Berkó Szilvia  |e aut 
700 0 1 |a Erős Gábor  |e aut 
700 0 1 |a Boros Mihály  |e aut 
700 0 1 |a Horváth Gyöngyi  |e aut 
700 0 1 |a Varga Endre  |e aut 
700 0 1 |a Csányi Erzsébet  |e aut 
856 4 0 |u http://publicatio.bibl.u-szeged.hu/13810/1/Hartmann_et_al_dddt_161703_electroporation_enhanced_transdermal_drug_delivery_into_the__062618_u.pdf  |z Dokumentum-elérés